Index Pharmaceuticals: InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod

STOCKHOLM, Dec. 8, 2021 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical pharmacokinetic study (PK study) with

Related Keywords

Sweden ,Stockholm ,Peter Zerhouni ,Prnewswire Index Pharmaceuticals Holding ,Kindex Pharmaceuticals ,Lancet Gastroenterology ,Dex Pharmaceuticals ,Immunomodulatory Sequences ,Nasdaq First North Growth Market ,Addex Pharma ,Index ,Pharmaceuticals ,Nrols ,First ,Patient ,Study ,Cobitolimod ,